UPDATE: Bank Of America On Immunomedics Notes Co's ADC Sacituzumab Govitecan In Triple Negative Breast Cancer 'showed a 33% overall response rate (ORR) in third-line in ph 2 study, which we view positively' Has Potential To Disrupt Current Paradigm